Value of metalloproteinases in predicting COPD in heavy urban smokers.
Publication/Presentation Date
9-2-2020
Abstract
BACKGROUND: Emphysema in asymptomatic heavy smokers can be detected during CT-scan screening for lung cancer. Metalloproteinases (MMPs) have been found to play a role in the pathogenesis of chronic obstructive pulmonary disease and to possibly serve as biomarkers for emphysema.
METHODS: The NYU Lung Cancer Biomarker Center enrolled study subjects over 50 years of age with lung cancer risk factors from January 1, 2010, to December 31, 2015. These subjects received chest multi-detector computed tomography, spirometry, and provided serum for immunoassays for metalloproteinases (MMP) -1, -2, -7, -9, -10 and tissue inhibitor of metalloproteinases (TIMP) -1 and -2.
RESULTS: Three hundred sixteen study subjects were enrolled. Of the 222 patients who met the inclusion criteria, 46% had emphysema. Smokers with emphysema had increased pack-years of smoking compared to smokers without emphysema (51 ± 24 pack-years (mean ± sd) versus 37 ± 20; p < 0.0001). Smokers with emphysema also had lower FEV
CONCLUSION: Emphysema was detected by CT in almost half of heavy urban smokers. Serum MMP levels provided minimal additional information to improve the detection of mild emphysema among smokers given their clinical characteristics (age, pack-years, and FEV
Volume
21
Issue
1
First Page
228
Last Page
228
ISSN
1465-993X
Published In/Presented At
Tsay, J. J., Hu, Y., Goldberg, J. D., Wang, B., Vijayalekshmy, S., Yie, T. A., Bantis, K., Sterman, D. H., & Rom, W. N. (2020). Value of metalloproteinases in predicting COPD in heavy urban smokers. Respiratory research, 21(1), 228. https://doi.org/10.1186/s12931-020-01496-9
Disciplines
Medicine and Health Sciences
PubMedID
32878618
Department(s)
Department of Medicine
Document Type
Article